Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857359 · ClinicalTrials.gov registry record · Phase 2
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
A Phase 2 study, sponsored by Addex Pharma S.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04857359 is a Phase 2 study that was terminated before completion, run by Addex Pharma S.A.. The registered enrollment target is 25 participants.
The verdict
NCT04857359, a Phase 2 study, was terminated before completion, sponsored by Addex Pharma S.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Interventions
- DRUG Placebo
- DRUG Dipraglurant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857359
The ClinicalTrials.gov registry entry for NCT04857359 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Addex Pharma S.A., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04857359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04857359 about?
NCT04857359 is a clinical study titled "Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy". This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rati...
What is the current status of trial NCT04857359?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-08-06. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT04857359?
The interventions under investigation include: Placebo (DRUG), Dipraglurant (DRUG).
Who is sponsoring clinical trial NCT04857359?
This trial is sponsored by Addex Pharma S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.